Zealand Pharma — September 2024
-
Ja, det var en pæn stigning i short på 0,8%….”nogen” prøver at udnytte den usikkerhed som insidersalg skaber
Jeg tillægger det nu ikke den store betydning, da Adam vel “bare”
er ramt af lagerbeskatning -
tak PI og @Stroka
-
Zealand Pharma inkluderet i MSCI World
https://www.indeksinvest.dk/msci-fjerner-stort-antal-kina-selskaber-og-tilfoejer-nye-fra-indien-og-zealand-pharma/ -
OVERBLIK onsdag d. 4. september 2024: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1208924/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
OVERBLIK d. 5. september 2024: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1209514/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Zealand Pharma kritik https://proinvestor.com/boards/122127/
-
Godmorgen
-
God morgen
-
"Til gengæld var der salgspres på sundhedsaktierne med et fald til Novo-konkurrenten Eli Lilly på 3,6 pct., ligesom USA's største sygekasse, Unitedhealth, mistede 1,4 pct. Abbvie tabte også 2,1 pct. - Sundhed, som er en defensiv sektor, har klaret sig ret godt i den senere tid, da den måske er lidt ligesom teknologiaktierne - en sikker havn under recession. Sektoren har outperformet, og så tager man noget gevinst og rykker rundt....
-
Sundhed kunne godt ligne en fundingkandidat til torsdagens køb af teknologiaktier, mener Danske Banks investeringsstrateg. https://proinvestor.com/investornyt/1210079/usa-lukning-eli-lilly-trak-aktier-i-rodt-tesla-og-amazon-loftede
-
Diabetes præparater: Interessant sydkoreansk demens studie https://proinvestor.com/boards/122128
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1211016/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Roche er i modvind på fedmekandidat https://proinvestor.com/investornyt/1211195/roche-er-i-modvind-pa-fedmekandidat
-
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses
Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies -
Læs hele meddelelsen: https://proinvestor.com/boards/122170
-
Mandagens aktier: Zealand i slutspurt i generelt positivt marked https://proinvestor.com/investornyt/1211235/mandagens-aktier-zealand-i-slutspurt-i-generelt-positivt-marked
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind